Sarnak, M. J. et al. Chronic kidney disease and coronary artery disease: JACC state-of-the-art review. J. Am. Coll. Cardiol. 74, 1823–1838 (2019).
Kanellis, J. & Kang, D. H. Uric acid as a mediator of endothelial dysfunction, inflammation, and vascular disease. Semin. Nephrol. 25, 39–42 (2005).
Sanchez-Lozada, L. G. et al. Mild hyperuricemia induces vasoconstriction and maintains glomerular hypertension in normal and remnant kidney rats. Kidney Int. 67, 237–247 (2005).
Kubo, S. et al. Higher serum uric acid level is inversely associated with renal function assessed by cystatin C in a Japanese general population without chronic kidney disease: The KOBE study. BMC Nephrol. 20, 117 (2019).
Satirapoj, B. et al. Relationship between serum uric acid levels with chronic kidney disease in a Southeast Asian population. Nephrology (Carlton) 15, 253–258 (2010).
Virdis, A. et al. Identification of the uric acid thresholds predicting an increased total and cardiovascular mortality over 20 years. Hypertension 75, 302–308 (2020).
Su, X., Xu, B., Yan, B., Qiao, X. & Wang, L. Effects of uric acid-lowering therapy in patients with chronic kidney disease: A meta-analysis. PLoS ONE 12, e0187550 (2017).
Zhang, X., Wan, D., Yang, G., Peng, Q. & Wang, X. Febuxostat is superior to allopurinol in delaying the progression of renal impairment in patients with chronic kidney disease and hyperuricemia. Int. Urol. Nephrol. 51, 2273–2283 (2019).
Becker, M. A. et al. Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: A twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout. Arthritis Rheum. 52, 916–923 (2005).
White, W. B. et al. Cardiovascular safety of febuxostat or allopurinol in patients with gout. N. Engl. J. Med. 378, 1200–1210 (2018).
Liu, X. et al. The urate-lowering efficacy and safety of febuxostat versus allopurinol in Chinese patients with asymptomatic hyperuricemia and with chronic kidney disease stages 3–5. Clin. Exp. Nephrol. 23, 362–370 (2019).
Sanchez-Lozada, L. G. et al. Effect of febuxostat on the progression of renal disease in 5/6 nephrectomy rats with and without hyperuricemia. Nephron Physiol. 108, p69-78 (2008).
Omori, H. et al. Use of xanthine oxidase inhibitor febuxostat inhibits renal interstitial inflammation and fibrosis in unilateral ureteral obstructive nephropathy. Clin. Exp. Nephrol. 16, 549–556 (2012).
Zoccali, C., Maio, R., Mallamaci, F., Sesti, G. & Perticone, F. Uric acid and endothelial dysfunction in essential hypertension. J. Am. Soc. Nephrol. 17, 1466–1471 (2006).
Kimura, K. et al. Febuxostat therapy for patients with stage 3 CKD and asymptomatic hyperuricemia: A randomized trial. Am. J. Kidney Dis. 72, 798–810 (2018).
Peng, Y. L. et al. Comparison of uric acid reduction and renal outcomes of febuxostat vs allopurinol in patients with chronic kidney disease. Sci. Rep. 10, 10734 (2020).
Alshahawey, M., Shahin, S. M., Elsaid, T. W. & Sabri, N. A. Effect of febuxostat on the endothelial dysfunction in hemodialysis patients: A randomized, placebo-controlled, double-blinded study. Am. J. Nephrol. 45, 452–459 (2017).
Tsuruta, Y. et al. Febuxostat improves endothelial function in hemodialysis patients with hyperuricemia: A randomized controlled study. Hemodial. Int. 19, 514–520 (2015).
Shibagaki, Y., Ohno, I., Hosoya, T. & Kimura, K. Safety, efficacy and renal effect of febuxostat in patients with moderate-to-severe kidney dysfunction. Hypertens. Res. 37, 919–925 (2014).
Mwasongwe, S. E. et al. Relation of uric acid level to rapid kidney function decline and development of kidney disease: The Jackson Heart Study. J. Clin. Hypertens. (Greenwich) 20, 775–783 (2018).
Lee, S. J., Oh, B. K. & Sung, K. C. Uric acid and cardiometabolic diseases. Clin. Hypertens. 26, 13 (2020).
Johnson, R. J. et al. Hyperuricemia, acute and chronic kidney disease, hypertension, and cardiovascular disease: Report of a scientific workshop organized by the National Kidney Foundation. Am. J. Kidney Dis. 71, 851–865 (2018).
Sampson, A. L., Singer, R. F. & Walters, G. D. Uric acid lowering therapies for preventing or delaying the progression of chronic kidney disease. Cochrane Database Syst. Rev. 10, CD009460 (2017).
Kojima, S. et al. Febuxostat for cerebral and cardiorenovascular events prevention study. Eur. Heart J. 40, 1778–1786 (2019).
Yilmaz, M. I. et al. The determinants of endothelial dysfunction in CKD: Oxidative stress and asymmetric dimethylarginine. Am. J. Kidney Dis. 47, 42–50 (2006).
Alem, M. M. Allopurinol and endothelial function: A systematic review with meta-analysis of randomized controlled trials. Cardiovasc. Ther. 36, e12432 (2018).
Alshahawey, M., Shaheen, S. M., Elsaid, T. & Sabri, N. A. Effect of febuxostat on oxidative stress in hemodialysis patients with endothelial dysfunction: A randomized, placebo-controlled, double-blinded study. Int. Urol. Nephrol. 51, 1649–1657 (2019).